Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and
functions as an important regulator of cell proliferation and cell survival in various B cell …

Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1
and the cell cycle, disruption of DNA damage response pathways, and activation of cell …

Background Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling
pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a …

Certain malignant B cells rely on B-cell receptor (BCR)–mediated survival signals. Spleen
tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in vivo analyses of B-cell …

The physiology of B cells is intimately connected with the function of their B‐cell receptor
(BCR). B‐cell lymphomas frequently (dys) regulate BCR signalling and thus take advantage …

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma of which at least a subset
arises from antigen-experienced B cells. However, what role antigen stimulation plays in its …

Mantle cell lymphoma (MCL) is a well-defined lymphoid malignancy characterized by a
rapid clinical evolution and poor response to current therapeutic protocols. The genetic and …

Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its
ability to couple immune cell receptors to intracellular signaling pathways that regulate …

Abstract Ibrutinib (PCI-32765) is a highly potent oral Bruton tyrosine kinase (BTK) inhibitor in
clinical development for treating B-cell lymphoproliferative diseases. Patients with chronic …

The role of B-cell receptor (BCR)–mediated survival signals in diffuse large B-cell lymphoma
(DLBCL) remains undefined. Ligand-induced BCR signaling induces receptor …